Related Experiment Videos
Pre-transfusion screening for platelet-reactive antibodies.
Tetsunori Tasaki1, Kieko Fujii, Kenji Gotoh
1Department of Blood Transfusion and Testing, Iwate Medical University Hospital, Japan. ttasaki@iwate-med.ac.jp
Summary
Screening patients for platelet-reactive antibodies before transfusion significantly reduces costs. Pre-transfusion screening ensures timely platelet concentrate (PC) availability, avoiding multiple transfusions and lowering overall healthcare expenses.
Area of Science:
- Transfusion Medicine
- Immunology
- Health Economics
Background:
- Platelet-reactive antibodies can complicate transfusion therapy.
- Determining the optimal timing for antibody screening is crucial for patient management and cost-effectiveness.
Purpose of the Study:
- To compare the costs associated with platelet concentrate (PC) usage based on the timing of platelet-reactive antibody screening.
- To evaluate the clinical and economic impact of pre-transfusion antibody screening versus post-transfusion screening.
Main Methods:
- Retrospective analysis of 774 patients' data.
- Comparison of mean PC costs between two groups: pre-screened and post-treatment screened.
- Evaluation of transfusion outcomes and associated costs.
Main Results:
- The mean cost of PCs for patients screened after treatment initiation ($5562) was substantially higher than for those screened beforehand ($2547).
- Pre-transfusion screening facilitated prompt access to specific PCs, minimizing the need for repeated transfusions.
Conclusions:
- Screening for platelet-reactive antibodies prior to administering platelet concentrates is clinically and economically advantageous.
- This approach optimizes resource utilization and reduces overall healthcare expenditure in transfusion medicine.